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Abstract: 
Objective: Cortical grey matter (GM) pathology, involving demyelination and 
neurodegeneration, associated with meningeal inflammation, could be important in 
determining disability progression in multiple sclerosis (MS). However, we need to know 
more about how cortical demyelination, neurodegeneration and meningeal inflammation 
contribute to pathology in early stages of MS to better predict long-term outcome.  
Methods: Tissue blocks from short disease duration MS (n=12, median disease duration 2 
years), progressive MS (n=21, disease duration 25 years), non-diseased controls (n=11) and 
other neurological inflammatory disease controls (n=6), were quantitatively analysed by 
immunohistochemistry, immunofluorescence and in situ hybridisation. 
Results: Cortical GM demyelination was extensive in some cases of acute MS (range 1– 
48% of total cortical GM) and subpial lesions were the most common type (62%). The 
numbers of activated (CD68+) microglia/ macrophages were increased in cases with subpial 
lesions and the density of neurons was significantly reduced in acute MS normal appearing 
and lesion GM, compared to controls (p<0.005). Significant meningeal inflammation and 
lymphoid-like structures were seen in 4 of 12 acute MS cases. The extent of meningeal 
inflammation correlated with microglial/ macrophage activation (p<0.05), but not the area of 
cortical demyelination, reflecting the finding that lymphoid-like structures were seen adjacent 
to GM lesions as well as areas of partially demyelinated/remyelinated, cortical GM.  
Interpretation: Our findings demonstrate that cortical demyelination, neuronal loss and 
meningeal inflammation are notable pathological hallmarks of acute MS and support the 
need to identify early biomarkers of this pathology to better predict outcome.    
  
Introduction:  
Multiple sclerosis (MS) is a highly variable and life-changing condition, characterised by 
inflammation, demyelination and neurodegeneration. MS typically presents as a relapsing-
remitting disease, where bouts of acute inflammation and new, active, demyelinating lesions 
are associated with neurological impairment. Lesions of the grey matter (GM) occur at all 
stages of the disease and the extent of cortical GM pathology predicts conversion to 
clinically definite MS and associates with cognitive and motor disability, epilepsy and an 
earlier transition to the progressive phase1.  
Recent findings suggest that subpial GM lesions of the neocortex, the principal lesion type of 
the MS cortex, are related, at least in part, to inflammatory activity in the overlying 
leptomeninges2. We and others have shown how the degree of meningeal inflammation 
correlates with cortical microglial activation, neuritic and neuronal degeneration, and 
demyelination in primary progressive and secondary progressive MS3–10. Inflammatory cells 
of the leptomeninges (T- and B-lymphocytes, plasma cells and macrophages) are increased 
in number, can display a semi-organised lymphoid-like structure, and are typically seen in 
the deep cerebral sulci, but are also noted in the leptomeninges of the cerebellum and spinal 
cord3,11,12.  
Lymphoid-like structures (LLS), which can resemble ectopic B-cell follicles seen in other 
autoimmune diseases13, are observed in models of MS and in approximately 40% of 
secondary progressive MS cases at post-mortem5. Cases of progressive MS harboring 
elevated leptomeningeal immune cell infiltration and LLS are associated with an early onset, 
shorter and more aggressive disease course, and accumulated disability more rapidly than 
those in which LLS could not be identified5. More recently, it has also been demonstrated 
that a signature of immune mediators important in lymphocyte homing and 
lymphoidogenesis, strongly predicts those people with early MS at risk of an extensive 
neocortical atrophy and MRI-visible cortical lesions14.  
We analysed a post-mortem cohort of MS cases with a short disease duration, who were 
diagnosed and died before the advent of disease modifying therapies. We asked the 
question if cortical lesions and neuronal loss are a feature of acute MS and if leptomeningeal 
inflammation is a notable pathological feature in the earliest stages of the clinical disease. 
These findings help us better understand the pathogenetic mechanisms of cortical GM 
pathology in early disease and may have implications for the rational identification of 
prognostic molecular and/or radiological measures for this heterogeneous condition.   
 
Methods:  
Cohort demographics: Human post-mortem tissue samples (South West Wales Research 
Ethics Committee approval #13/WA/0292) provided by the Thomas Willis Oxford Brain Bank 
and the Queen's University Belfast ‘Dame Ingrid Allen Demyelinating Diseases’ Tissue 
Collection were used to investigate the pathological features present in the earliest stages of 
MS. Cases of chronic progressive MS (primary and secondary progressive with disease 
duration >10 years) were provided by the UK MS Society Tissue Bank, Imperial College 
London (ethical approval #08/MRE09/31+5). Details of each case are listed in Table 1.   
Six μm thick, formalin fixed paraffin embedded sections were cut from cerebral cortex and 
subcortical white matter blocks obtained from the superior frontal cortex, cingulate gyrus, 
occipital lobe and anterior hippocampus/para-hippocampal gyrus. Twelve cases of acute MS 
(9 female) were selected based on tissue availability and their short disease duration 
(median duration of 2 years (range 0.3y-4y), median age at death 35 years (range 22y-58y), 
Table 1). The cases of progressive MS represented a cohort of clinical and 
neuropathologically validated MS with evidence of active disease pathology, and comprised 
a minimum of three tissue blocks of frontal, cingulate and temporal cortex per case (primary 
progressive MS n=3, secondary progressive MS n=18, 12 female, median age at death 50 
(range 38y-66y), disease duration 25yrs (range 10y- 39y)).  Anatomically matched tissue 
blocks from eleven non-neurological disease controls were used for comparison. Control 
case selection was based on tissue availability, cause of death and the youngest possible 
age at death: age 56 years (range 41y-67y). In addition, we obtained tissue from six neuro-
inflammatory disease controls; acute disseminated encephalomyelitis (n=1), 
cytomegalovirus encephalitis (n=3), neuromyelitis optica (n=1) and co-morbid 
meningoencephalitis with multiple sclerosis (n=1) for qualitative analysis (see Table 1).  
Tissue characterisation and analysis: Tissue sections were stained with Luxol-Fast Blue and 
immunohistochemically stained with anti-proteolipid protein (PLP) and anti-CD68 antibodies 
to characterise demyelination and lesion inflammatory status, and parenchymal and 
meningeal connective tissue microglia/ macrophage density. Sections were assessed for the 
degree of grey and white matter demyelination, presence or absence of GM lesion types and 
presence of areas of  tissue that appeared to be partially de/re-myelinated cortical GM. 
Cortical GM lesions were categorised following published criteria15: Type 1 or leucocortical 
GM lesions, type 2 or intracortical lesions, type 3 or subpial lesions, or type 4 or cortex 
spanning lesions. GM lesions displaying CD68+ microglia/ macrophage numbers equivalent 
to adjacent normal appearing GM were regarded as chronic inactive. Lesions with increased 
numbers of CD68+ microglial/ macrophage, typically restricted to the demyelinating lesion 
edge and with evidence of PLP+ inclusions, were termed chronic active GM lesions. GM 
lesions with microglial/ macrophage activation throughout the lesion, and microglia/ 
macrophages containing inclusions of PLP+ material, were classified as active GM lesions.  
White matter lesions were categorised based on their relative inflammatory activity, in 
accordance with previous descriptions16,17. White matter lesions were grouped as: (i) Active 
and demyelinating, displaying extensive CD68+ cells throughout the lesion with PLP+ 
inclusions within microglia/ macrophages; (ii) active and post-demyelinating, displaying 
extensive CD68+ cells but lacking PLP+ inclusions in microglia/ macrophages; (iii) chronic 
active lesions, displaying CD68+ cells at the lesion edge, often with evidence of active 
demyelination; and (iv) inactive lesions, with little increase in the number of CD68+ 
microglia/ macrophages at the lesion edge and no evidence of recent myelin phagocytosis. 
Fully remyelinated white matter lesions were classified as shadow plaques based on the 
‘normally appearing’ PLP profile and classic Luxol Fast Blue ‘shadow’ appearance18, whilst 
partial or incompletely remyelinated areas were referred to as remyelinating lesions. We 
acknowledge that the above characterisation only refers to the sampled area of incomplete 
lesions as present in standard histology sections17. 
The relative inflammatory status of cases was graded by assessing the degree of total 
cellular infiltration (Nissl counter-stained cellular infiltrates) of grey and white matter vessels 
and the meninges5. Briefly: absence or mild inflammation was rated 0+ (zero to 5 cells), 
diffuse and modest inflammation was rated ++ (equivalent to an infiltrate of 5–50 loosely 
packed cells in perivascular space or meninges); or more substantial infiltration was rated 
+++ (based on >50 cells in a tightly packed infiltrate, characteristic of a putative lymphoid-
like structure). 
Immunohistochemistry: Individual antibody details are listed in table 2. Briefly, following 
dewaxing, rehydration, epitope retrieval and blocking, slides were incubated with primary 
antibody overnight. Species-specific biotinylated secondary antibody (raised in horse or 
goat, Vector Laboratories, Peterborough, Cambridgeshire, UK) was applied and antibody 
binding visualised with the avidin-biotin-complex (ABC) peroxidase-linked reporter system, 
with 3, 3’-diaminobenzidine (DAB; Impact DAB; Vector Laboratories) as the chromogen. 
Tissue sections were counterstained with haematoxylin and DPX mounted. Dual colour 
immunohistochemistry was performed sequentially: Primary antibody 1 was detected using 
the IMPRESS-peroxidase detection kit (Vector), using DAB as the reporter chromogen. 
Primary antibody 2 was detected using the ABC- alkaline phosphatase detection system, 
using Vector Blue as the substrate. When using two primary antibodies raised in the same 
species (for dual CD20 and anti-PCNA), the slides were subjected to an additional round of 
heat-retrieval in between the detection of primary antibody 1 and primary antibody 2, as 
described previously19.  
For immunofluorescence, relevant primary antibodies were amplified using the IMPRESS 
Dylight reaction kit (Vector Labs) or via biotin- streptavidin-fluorophore (Alexa 488 or Alexa 
546) conjugates (MerckMillipore, Watford, UK).  All sections were counterstained with 4',6-
diamidino-2-phenylindole, dihydrochloride; DAPI (Sigma).  
Images were acquired with a Zeiss Axio Imager M1 microscope and a Carl Zeiss AxioCam 
MRm monochrome camera (epifluorescence) or an AxioCam HRm (for brightfield 
microscopy). Negative controls were included and in all instances the relevant IgG control, or 
the absence of the secondary detection antibody, yielded no signal.   
In situ hybridisation: In situ hybridisation (ISH) was performed using a 5’ fluorescein (FAM)-
labelled 19mer antisense oligonucleotide containing locked nucleic acid (LNA) and 2’-O-
methyl (2’-O-Me)-RNA moieties in a 1:2 ratio. Probe design: Antisense C1QA (NM_015991) 
FAM- TggTccTugAugTuuCcuG and Sense FAM- CagGaaAcaTcaAggAccA; Antisense C3 
(NM_000064) FAM- TagAaaGugAugGagAcuA and Sense FAM- AgaAauGauUggUggAuuA; 
Antisense CXCL13 (NM_006419) FAM- AuuGacTugTucTucTucC and Sense FAM- 
GgaAgaAgaAcaAguCaaT; (where capitals indicate LNA and lower case 2’-O-Methyl RNA in 
all instances; Eurogentec, Southampton, UK). ISH was performed as previously 
described20,21 and hybridisation and wash conditions optimised so that all sense probes 
yielded essentially no signal. Appropriate sense probes and no probe controls were included 
in every experimental run. Specifically bound oligo-probe was visualised with a peroxidase 
conjugated goat anti-FAM (Vector) and DAB. For dual ISH and immunostaining, anti-HuC/D, 
anti-CD20 or anti-IBA-1 antibody binding was detected using appropriate horse anti-mouse 
or anti-rabbit biotin conjugated secondary and avidin-biotin-Alkaline Phosphate tertiary 
complex with Vector Blue substrate.  
Quantitative morphometry: Histological or immunohistochemically stained tissue sections for 
LFB, PLP, CD68, CD3 and HuC/D were digitised by whole slide-scanning using a Leica 
SCF400F scanner. Image files were handled using QuPath22. To measure areas of 
demyelination, we first traced and measured the entire grey and white matter fraction for 
each LFB/haematoxylin stained slide using QuPath, before measuring the area of individual 
grey and white matter lesions on the serial PLP/haematoxylin stained section. Mean GM and 
white matter lesion area was reported per section and per case as the percentage of total 
grey or white matter, respectively. Using the ‘Positive Cell Detection of a region of interest’ 
tool in QuPath, a quantification of CD68+ microglia/ macrophages and HuC/D+ neurons was 
performed across the entire depth of the cortical ribbon- from the pial surface to the grey/ 
white matter boundary (count per mm2 of the region of interest, minimum sampled area per 
region of interest= 2mm2). The number of parenchymal CD68+  microglia/ macrophages and 
the number of meningeal CD68+ macrophages and CD3+ T-cells (per mm of intact 
meninges), was determined. 
Measuring myelin coverage and defining partially de/re-myelinated cortical grey matter: We 
used FIJI ImageJ (https://fiji.sc/) to determine the myelin coverage across the GM cortex in 
virtual x40 magnification PLP snapshots exported from QuPath (image size 2.25x 3.75mm). 
TIFF image snapshots were converted to greyscale before thresholding to mark all areas 
positive for anti-PLP specific immunostain. Myelin density profiles were generated for the 
entire depth of the cortical ribbon from areas of ‘most normal’ myelin and partially de/re-
myelinated GM, in the same block and at the same architectonic point (i.e. sampled from 
base of sulcus or midway between sulcus and crown of gyrus) using the plot-profile selection 
tool. Myelin density profiles (captured in triplicate) were averaged and reported for every 2% 
step along the depth of the sampled cortex. Density profiles at each step were then 
compared relative to the same point in the myelin density profile of matched ‘most normal’ 
GM as described in the results and legend.    
Statistical analysis: Results were presented as scatter dot plots with a line at the mean or as 
box and whiskers plots showing min-to-max values, interquartile range and group medians. 
Two-group comparisons were made using the Mann-Whitney U test or Wilcoxon matched 
pairs test, whilst three or more groups were compared by non-parametric one-way ANOVA 
(Kruskal-Wallis test), using Dunn’s multiple comparisons post-test. Associations between 
pathological variables were tested by Spearman analysis (GraphPad PRISM v6).  
Results: 
Cortical grey and white matter demyelination in acute MS:  
Anti-PLP immunostaining revealed extensive areas of white matter demyelination and all 
four cortical GM lesion types in acute MS (Fig 1A- D). Demyelinated cortical GM (as a 
percentage of total cortical GM) ranged from 1-48% (mean 11.9%, Fig 1E), whilst WM 
demyelination ranged from 2-81%. Average white matter lesion area was significantly 
greater than GM lesion area (34.3% versus 11.9%, p=0.0007) at this stage. Progressive MS 
cortex had three-times the extent of cortical GM demyelination as seen in acute MS (29.1% 
versus 11.9%, in progressive and acute MS, respectively, p=0.03), with the area of GM 
demyelination being comparable to that of white matter lesions in the same progressive MS 
cases (29.1% and 30.1%, for grey and white matter lesions, respectively).   
Subpial (type 3) cortical GM lesions were the most abundant cortical GM lesion type in acute 
MS (seen twice as frequently as all other GM lesion types combined, Fig 1F). A number of 
small type 2 intracortical lesions were noted in acute MS (accounting for 19% of all cortical 
GM lesions). Interestingly, the proportion of type 3 GM lesions was remarkably similar in 
progressive MS but we failed to observe a single type 2 lesion in late disease. We noted an 
increase in the number of type 1 and type 4 GM lesion types (Fig 1F) in progressive cases. 
Over 50% (36 of 69) of the GM lesions displayed signs of active demyelination (active or 
chronic active GM lesions, Fig 1G), with 12 of 69 GM lesions being categorised as fully 
active cortical GM lesions (being confluent in CD68+ microglia/ macrophages containing 
PLP+ inclusions; Figure 1H- K). Only chronic active and chronic inactive cortical GM lesions 
were seen in progressive MS. Those cases displaying type 3 cortical GM lesions had 
significantly elevated numbers of anti-CD68+ microglia/ macrophages across the full depth 
of the cortex, in comparison to those acute MS cases without type 3 lesions (p=0.001) or in 
comparison to non-neurological controls (p=0.0002; Fig 1L). 
Neurodegeneration in acute MS: 
A significant reduction in total HuC/D+ neuron density was observed in MS normal 
appearing GM (NAGM, 19.7% reduction, p=0.0117) and MS GM containing type 3 lesions 
(GML, 34.3% reduction, p<0.0001), in comparison to anatomically matched controls (Fig 2A, 
B). 
We have previously shown that complement is activated in progressive MS GM neurons and 
complement activation correlated with severity of GM pathology21,23, whilst others have 
shown complement C1q and C3b expression is associated with degenerating synapses in 
the progressive MS hippocampus20. We performed ISH for complement transcripts that 
encode the recognition fragment C1q and the central complement component C3. We saw 
evidence of, but did not quantify, complement transcript positive cells with a distinct neuronal 
morphology associated with IBA-1+ microglia (Figure 2C), C1QA and C3 transcript positive 
cells with a neuronal morphology (Fig 2D, E) and C1QA positive cells dual labeled with anti-
HuC/D (Fig 2F, G).  
White matter lesions in acute MS: 
The majority of acute MS white matter lesions were classified as active inflammatory 
demyelinating lesions (Fig 3A- D), as might be expected for such a short disease duration 
cohort. Active white matter lesions accounted for 74% of all identified white matter lesions 
(39 lesions in total) in acute MS. The density of CD68+ microglia/ macrophages was 
significantly elevated in active white matter lesions in comparison to chronic active lesions, 
remyelinating and/ or shadow plaques, normal appearing white matter (NAWM) and control 
white matter (Fig 3E, F).   
Identification of leptomeningeal lymphoid-like structures (LLS) in acute MS: 
Semi-quantitative analysis of the extent of perivascular and meningeal immune cell infiltrates 
revealed 4 of 12 acute MS cases with extensive (rated +++) leptomeningeal cell infiltrates. 
Cases with extensive perivascular and leptomeningeal infiltrates also contained a greater 
proportion of cortical GM lesions classified as active or chronic active, in comparison to 
chronic inactive (Fig 4A). These four cases accounted for 65% of all active and chronic 
active GM lesions seen in the acute MS cohort. LLS of the acute MS leptomeninges were 
associated with a widespread and elevated number of macrophages (CD68+), T-cells 
(CD3+) and B-cells (CD20+) throughout the preserved leptomeninges (Fig 4B- D). Dense 
aggregates of leptomeningeal immune cell infiltrates, containing CD20+ B-cells and CD3+ T-
cells, were noted in these four cases (Fig 4E). CD8+ cytotoxic T-cells were evident in 
meningeal LLS (Fig 4F), along with B-cells co-expressing the marker of cell division PCNA, 
and leukocytes expressing transcripts of the key lymphogenic cytokine CXCL13 (Fig 4G, H).  
The relationship between meningeal infiltrates, parenchymal microglial activation and myelin 
pathology in acute MS: 
LLS in secondary progressive MS are typically associated with underlying areas of subpial 
cortical microglial activation and demyelination. Here we report a significant and robust 
association between the number of leptomeningeal macrophages and CD3+ lymphocytes 
(and a trend for CD20+ B-lymphocytes, r= 0.69, p= 0.07)) with the number of activated 
microglia/ macrophages in the subpial GM parenchyma in those acute MS cases with LLS 
(Table 3). It was interesting to note that alongside LLS, which were topographically 
associated with subpial GM lesions, we sometimes saw LLS next to areas of incompletely 
de/re-myelinated cortex  (Fig 5A- H). Areas of partially de/re-myelinated cortical GM were 
identified based on a direct comparison to the most normal appearing GM in the same 
section to moderate the effect of the natural variation in myelination between cortical areas. 
We observed that the density of PLP+ immunostaining was reduced by up to 70% in the 
partially de/re-myelinated cortical GM in comparison to paired samples of adjacent NAGM. 
The area of significantly reduced PLP+ signal extended from the pia to almost halfway 
across the depth of the cortex (on average 48% of the distance from the pia to the grey/white 
matter border; Fig 5I). Within this same tissue, the number of parenchymal CD68+ microglia/ 
macrophages was significantly elevated in the partially de/re-myelinated cortical GM in 
comparison to matched samples of NAGM, whilst the number of meningeal CD68+ 
macrophages was increased in areas overlaying the affected cortical GM in comparison to 
the same areas of adjacent NAGM (Fig 5J, K). The number of CD3+ and CD20+ 
lymphocytes was unchanged in the meninges overlying the partially de/re-myelinated GM in 
comparison to normal GM (data not shown). Supporting the impression that the partially 
de/re-myelinated GM may represent, at least in part, a pathological change, we noted 
CD68+ microglia containing PLP+ inclusions of myelin and evidence of neurofilament-H+ 
neuritic transections and end-bulb like structures in the affected GM (Fig 5L- M).  
 
Discussion: 
We report that subpial cortical demyelination, neurodegeneration and widespread microglia/ 
macrophage activation, together with elevated meningeal inflammation and the presence of 
lymphoid-like structures, are notable pathological features in the earliest years since 
diagnosis in some acute MS cases. These data have implications for our understanding of 
the pathology underlying MS and support efforts to develop biomarkers of meningeal 
inflammation and cortical demyelination early in the disease, to aid the identification of those 
at risk of a more severe MS course. 
 
Grey matter demyelination is widespread and active in acute MS:  
The majority of neuropathological studies of cortical pathology have been conducted on 
cases of long-standing, progressive disease2, and it has been suggested that the build-up of 
cortical damage may be more prominent at the later stages9,10. Here we analysed an 
archival cohort in what is, at present, the largest study of cortical pathology in acute MS. The 
cohort is defined by a short disease duration, which we have termed acute MS, and all 
patients died before the advent of effective anti-inflammatory therapies. Cases of such short 
disease duration are rare, given the success of current immunomodulatory therapies. 
Therefore, this tissue cohort provides an important resource for the description of cortical 
pathology, including demyelination, neurodegeneration and inflammation, in the early 
clinically apparent phase of the disease. 
 
Cortical grey matter lesions, especially subpial (or type 3) GM lesions, were frequently noted 
in both our acute and progressive MS cohorts. Cortical pathology and significant subpial 
demyelination have also been documented in biopsy tissue taken as part of the diagnosis of 
MS with an atypical presentation24. In contrast to our study, Kutzelnigg et al, reported only 
modest cortical demyelination (0- 4% of total cortical GM measured from coronal 
macrosections) in a cohort of acute MS. Differences may partly be explained by the shorter 
disease duration (up to 7 months compared to 4 years in this study), a younger age at death 
leading to a more aggressive cortical pathology in our cohort, or that our sampling of small 
blocks (1- 6 blocks per case) over-estimates what might be a highly variable pattern of 
cortical demyelination when viewed across the whole forebrain. However, these findings do 
suggest that the mechanisms that drive cortical lesion formation in acute MS may be the 
same as those that contribute to cortical pathology in long-term disease and are already 
present at an early stage. Subpial cortical lesion pathogenesis is associated with 
inflammation of the overlying leptomeninges3,8,9. Progressive cases with significant 
leptomeningeal inflammation at post-mortem had a gradient of neuronal, neuritic and glial 
cell loss4, which are substrates for cortical thinning and atrophy measured by MRI25. High 
resolution T2* weighted MRI has highlighted that the greatest changes affect the outer 25% 
of the cortex in the earliest stage of the disease and that these signal changes are most 
significant in the sulci- a common site of subpial lesion pathology5,26. More generally, those 
patients with more cortical lesions and/or greater cortical atrophy, have greater cognitive 
dysfunction and attain disability milestones more rapidly27–30, whilst cognitive and 
neuropsychiatric dysfunction are important indicators of cortical pathology even in the 
absence of classical MS clinical features31. Our finding of subpial lesions in a cohort who 
died following a short disease course supports a key role for cortical pathology in the 
disease outcome. This report adds weight to the recognised need to be able to detect 
subpial lesions in vivo so that we have a more complete picture of the patient’s disease. 
 
Numerous, small, intracortical lesions (type 2 lesions) were seen in early but not in 
progressive MS. Type 2 lesions are the least common cortical GM lesion and account for the 
smallest area of demyelination in progressive MS. The increased proportion of larger type 1 
and type 4 lesions in later disease may account for this change- whereby the smaller type 2 
lesions are subsumed as part of larger, neighbouring, lesions.   
 
White matter lesions occupied a greater area than cortical grey matter lesions in acute MS, 
which could mean that white matter lesions are a dominant pathology site of injury in acute 
MS. It is important to note that the finding of significant WM demyelination may well reflect a 
selection bias in neuropathological studies. Selection of tissue blocks at initial brain 
dissection is typically based on the presence of macroscopically visible white matter lesions. 
Evidence for possible ascertainment bias is supported by our observation that WM lesion 
size was no different in later disease in samples selected based on anatomical region of 
interest rather than on available, visible, WM lesions. However, the suggested mechanisms 
involved in the formation of subpial lesions would mean that they are slower forming and 
might only accumulate over a longer period than acute white matter lesions. Our study was 
principally focussed on cortical, and not WM, pathology in early MS. Subpial cortical GM 
lesions cannot be seen macroscopically, meaning that blocks cannot be pre-selected for this 
lesion type. In addition, there was no suggestion of an association between the extent of WM 
demyelination and GM demyelination in acute MS (Spearman r= 0.06, p= 0.91; comparing 
lesion area per block), meaning that any bias in block ascertainment should not bias our 
principal research findings.  
 
Neurodegeneration occurs in the earliest years of the disease: 
Earlier neuropathology studies have suggested that inflammation is accompanied by axonal 
and neuronal pathology at all stages of the disease32. In agreement with this, we noted 
extensive neuron loss in acute MS GM lesions and normal GM in comparison to matched 
non-diseased controls.  The extent of neuron loss was comparable to that seen in the 
progressive MS cortex4,6,21,33, and of a similar magnitude to other GM structures34–36. The 
significant neurodegeneration in acute MS is supported by evidence that the majority of 
neuron loss in the spinal cord occurs early in disease37 and that in progressive MS the 
greatest neuronal loss is seen in those who experienced the shortest disease duration2. 
Neuronal stress and damage and eventual degeneration may be directly and/or indirectly 
driven by the local inflammation, perhaps as a consequence of serum protein leakage38, the 
diffusion of cytotoxic mediators from the CSF-filled compartments4,39, retrograde damage as 
a result of pathology along affected tracts7, and oxidative damage as a consequence of 
inflammation40 and/or mitochondrial dysfunction41. The density of activated (CD68+) tissue 
microglia/ macrophages was elevated in comparison to normal GM and control GM, which 
may cause, or be a consequence of, the neuron loss. Parenchymal T-cell infiltrates were 
noted, but were not quantitatively different between sampled regions (data not shown), whilst 
the number of parenchymal B-cells was negligible. These findings are different to those seen 
in some cortical GM lesions sampled en passant at biopsy, where significant parenchymal 
infiltrates were reported24. We believe this lack of compelling evidence for CD3+ T-cell or 
CD20+ B-cell infiltrates in the cortical parenchyma of cases with active GM lesions adds 
further weight to the important role that inflammation of the connective tissue, be it the 
perivascular space or meninges, might have in inducing local glial and neuronal damage and 
innate immune activation. Complement is a vital component of the innate immune system 
and complement over-activation sustains autoimmune disease. Complement activation is 
important in synaptic and neuritic destruction42, and complement positive neurons are seen 
in MS and other neurological conditions20,43–45. Complement positive neurons show signs of 
stress/damage and are dysmorphic21,23, and we show here that cortical neurons in acute MS 
express transcripts of key complement components. Therefore, not only is there significant 
focal neuronal loss but many surviving neurons express complement and are stressed or 
damaged, although we cannot conclude that neuronal complement activation is causal or in 
consequence to the degenerative change.  
 
Lymphoid-like structures (LLS) in MS cases of a short disease duration: 
Meningeal inflammation in MS has been linked to demyelination of the spinal cord, 
cerebellum and forebrain3,11,12 and similar subpial GM lesions can be induced by stereotactic 
injection of inflammatory cytokines into the leptomeningeal space of the rodent forebrain39. 
The meninges are an important site of antigen drainage, immune surveillance and 
inflammation, and ectopic lymphoid structures are commonly found in the connective tissues 
associated with other diseases of autoimmune or chronic inflammatory origin13. Such 
structures can be induced by T-follicular helper cells, cytokine networks and a changing 
stromal network of connective tissue cells, which may eventually support and sustain 
lymphocyte activation, B-cell selection and clonal expansion, and production of disease-
relevant pathogenic antibodies and other soluble mediators46.  
 
In keeping with our previous studies demonstrating semi-organised immune cell infiltrates 
that can often resemble ectopic tertiary lymphoid tissues, we noted lymphoid-like structures 
in four of twelve acute MS cases; an incidence similar to that seen in progressive MS and in 
other organ-specific autoimmune diseases5,13. The finding of LLS in early MS suggests that 
the burden of injury and/or organ-specific immune signals necessary for LLS formation are 
evident from the earliest times in some MS cases. LLS formation and maintenance 
accompany elevated tissue damage and antigen release46 and LLS+ early MS displayed a 
greater number of active cortical GM lesions, extensive neurodegeneration and elevated 
parenchymal microglia/ macrophage activation. Therefore, LLS could be an important sign of 
pathological disease activity at all stages of MS. In light of the above and because the 
presence of ectopic lymphoid tissues in synovial biopsies can stratify those in the early 
course of rheumatoid arthritis for treatment and is prognostic for outcome47,48, there is a 
justifiable need to identify LLS and enhanced leptomeningeal inflammation in people with 
MS. Recent data suggests that a cytokine/chemokine signature of lymphoidogenesis is 
elevated in CSF of MS cases with more cortical lesions and greater meningeal inflammation 
at post-mortem, and the same immune mediators accurately identify those patients 
presenting with an elevated cortical pathology on MRI at disease onset14. Such a combined 
biological and radiological approach, coupled with measurable clinical variables28, could 
therefore be more powerful in identifying those in the early stages of MS who are most at 
risk of a more severe disease course.  
  
Areas of partially de/re-myelinated cortical grey matter and associated meningeal 
inflammation: 
Together with an association with subpial cortical pathology, we noted that LLS were 
sometimes seen near areas of visibly reduced myelin density that may represent partially 
de/re-myelinated cortical GM. This affected GM was clearly not completely demyelinated 
GM, but was very different to region matched ‘most’ normal GM. The myelinated cortical GM 
in progressive MS displays significant synaptic, dendritic, axonal, neuronal and 
oligodendrocyte loss4,8,25. We noted that the partially de/re-myelinated GM contained 
increased numbers of activated microglia/ macrophages, microglia containing recently 
phagocytosed myelin debris, and damaged neurites. The cortical GM is efficiently 
remyelinated in MS and it’s models49 and is capable of repair following repeated episodes of 
demyelination50, but GM remyelination is difficult to measure at post-mortem. It would be 
important to understand how the partially de/re-myelinated cortical GM associates with 
nearby demyelination and tract specific pathology and to what degree the affected tissue 
represents early demyelination, incomplete remyelination or partially demyelinated GM.  
 
Alongside some of the limitations already discussed, we need to be cognisant of the fact that 
the study of demyelination in small tissue blocks is unlikely to represent the extent of 
pathology throughout the forebrain. Our findings may also be inadvertently biased in that our 
small blocks are sampled from brain regions which comprise some of the sites where cortical 
lesions are most frequently seen in later disease5,9,10. Tissue block sampling in this study 
was determined by the availability of suitable material. Additionally, we were unable to match 
controls and acute MS in terms of age at death (Table 1). Age is an important determinant of 
total neuron number in the adult brain51 and our findings of significant neuron loss in a 
younger cohort may have been underestimated.  
 
To conclude, we show that meningeal inflammation, neurodegeneration, cortical 
demyelination and a partially de/re-myelinated grey matter are notable pathological features 
of acute MS. Our results suggest that all of these pathologies may begin very early on in the 
clinical disease course and can already be substantial after 2 years since diagnosis. By 
combining biomarkers of intrathecal inflammation and neurodegeneration, together with the 
most sensitive imaging methods, it may yet be possible to predict those newly diagnosed 
with MS who are most at risk of early cortical pathology and the associated cognitive and 
motor disability, and therefore most in need of aggressive immunotherapy, for the best long-
term outcome.   
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Legends:  
Figure 1. Cortical demyelination in acute MS. Tissue from individuals with MS that died 
following a short disease duration (n=12) presented with cortical and subcortical lesions 
identified by anti-PLP immunostaining (A- D, arrows point to lesion edge). Cortical 
demyelination was variable and sometimes extensive in acute MS (E), whilst subpial cortical 
demyelination (type 3 cortical lesions) were seen most frequently (F). More cortical grey 
matter lesions were classified as active or chronic active in acute MS in comparison to 
progressive MS (G). Cortical demyelination was accompanied by microglia/ macrophage 
activation (CD68+; H, I; active and chronic active GM lesions, respectively), evidence of 
recent myelin phagocytosis (arrows highlighting PLP inclusions in IBA-1+ microglia/ 
macrophages, J- active GM lesion, K- chronic active GM lesion) and an overall increase in 
cortical microglia/ macrophages in acute MS normal and demyelinated grey matter in 
comparison to non-disease controls (L). Groups were compared by non-parametric Kruskal-
Wallis test with Dunn’s post-test. *= p<0.01, ***= p<0.0001. Abbreviations; Ctrl, control; GM, 
grey matter; GML, grey matter lesion; NAGM, normal appearing GM; WM, white matter; A, 
active inflammatory lesion; CA, chronic active inflammatory lesion; CI, chronic inactive 
inflammatory lesion. Scale bars, A- D= 5mm; H, I= 50µm; J, K= 5µm.  
 
Figure 2. Neurodegeneration in acute MS. The density of cortical HuC/D+ neurons was 
significantly reduced in normal appearing grey matter (NAGM) and lesion grey matter (GML) 
in comparison to matched control grey matter (Ctrl; A and B). We observed, but did not 
quantify, cells of acute MS cortex that expressed transcripts for the complement recognition 
protein C1Q, which were in close proximity to IBA-1+ microglia (C, arrow), C1QA and C3 
mRNA positive cells with a neuronal morphology (D, E), co-labeled with anti- HuC/D sera (F, 
HuC/D, highlighted by the arrow), whilst sense transcripts processed as part of the same 
experimental run were negative (G). Kruskal-Wallis test with Dunn’s post-test. *= p<0.01, 
***= p<0.0001, multiplicity adjusted p values quoted in the main text. Scale bars; B= 100µm, 
C, F, G= 20µm, D, E= 50µm.  
 
Figure 3. Inflammatory demyelination of the acute MS white matter. MS white matter 
lesions were classified as active inflammatory demyelinating lesions (A, A’, B, B’ anti-PLP 
immunostaining, A’’, B’’, anti-CD68), and further described as active white matter lesions 
with evidence of recent myelin phagocytosis (active and demyelinating (C, D, arrows 
showing IBA-1+ macrophages laden with anti-PLP positive material) and those lacking 
evidence of recent myelin phagocytosis (active and post-demyelinating; B). Active white 
matter lesions accounted for 74% of all identified white matter lesions (WM T), with chronic 
active (CA) lesions and remyelinating and/or shadow plaque lesions (RM/Sdw) less 
frequently observed (E). The density of CD68+ microglia/ macrophages reflected the state of 
active inflammation in early disease (F). Kruskal-Wallis and Dunn’s post-test. *= p<0.01, **= 
p<0.01, ***= p<0.0001. Scale bars; A, B= 200µm; A’- B’’, C, D= 50µm.    
Figure 4. Meningeal inflammatory infiltrates and lymphoid-like structures in acute MS. 
We scored the number of blocks harboring lymphoid-like structures (LLS) and rated the 
diffuse cellular infiltration of the meninges and parenchymal vessels (A). Four of 12 cases 
displayed evidence of meningeal LLS and contained areas of elevated connective tissue 
inflammation (meningeal/ perivascular inflammation).  Active cortical GM lesions (red), and 
chronic active GM lesions (dark grey), were noted in the LLS+ cases, whilst inactive GM 
lesions (light grey) were enriched in the cases lacking observable LLS or connective tissue 
infiltrates. LLS+ cases had significantly elevated numbers of meningeal CD68+ monocytes 
(B), CD3+ T-cells (C) and CD20+ B-cells (D) in comparison to LLS- and control cases (cells 
per mm length of meninges). Representative example of meningeal LLS containing CD20+ 
B-cells and CD3+ T-cells identified in case D192 (E). A LLS from case C0069 demonstrating 
the presence of CD8+ T-cells (F, red). LLS of the meninges contained dividing B-cells 
(CD20/PCNA+, G and inset with arrow) and CXCL13 transcript positive cells as part of a 
CD20+ immunostained meningeal infiltrate (H, with boxed areas captured at higher 
magnification. Arrows identify CXCL13+ ISH signal). Kruskal-Wallis and Dunn’s post-test. *= 
p<0.05, **= p<0.01, ***= p<0.0001.Scale bars: E, G, H= 100µm; F= 20µm.  
 
Figure 5. Characterising areas of partially de/re-myelinated cortical grey matter in 
acute MS. LLS were seen next to subpial cortical lesions and areas of partially de/re-
myelinated, but not fully demyelinated, grey matter (A, B; arrowhead indicates meningeal 
infiltrate and arrows indicate PLP+ lesion edge). Areas of partially de/re-myelinated cortical 
GM PLP+ myelin were visibly different to normal appearing GM in the same block (C- 
normal, D- affected GM) and line histograms were plotted in triplicate per region of normal or 
partially de/re-myelinated GM per case following image transformation and thresholding (E- 
H). Myelin coverage was averaged and reported for each 2% increment from the pia to the 
grey- white matter border and plotted relative to the ‘most normal’ grey matter measures 
taken from the same tissue block (I). Quantification revealed myelin coverage to be reduced 
by approximately 70% in the outer laminae in comparison to matched normal GM from the 
same block (p<0.05). Areas of quantitatively identified partially de/re-myelinated cortical GM 
(labeled as affected GM) displayed elevated numbers of parenchymal CD68+ microglia/ 
macrophages and were associated with elevated numbers of CD68+ macrophages in the 
overlying meninges (J, K). Areas of partially de/re-myelinated cortical GM containing 
microglia with inclusions of PLP (L; dual IHC for IBA-1 and PLP. L’- L’’ are higher resolution 
images from the partially de/re-myelinated area shown and arrows highlight IBA-1+ cells with 
PLP+ inclusions) and evidence of neurite damage (M, arrow highlights a neuritic end-bulb 
stained with anti-neurofilament-H). Unpaired t test, one per row, corrected for multiple 
comparisons using the Holm-Sidak method (I) or two-group comparisons using the Wilcoxon 
matched pairs test (J, K).  Scale bars: A-F, 3mm; L= 100µm; M= 20µm.   
  
Table 1: 
 
Acute MS Disease Gender Disease 
Duration, yr 
Age at 
Death, yr 
Cause of Death Available 
Blocks 
B8442 Acute MS F <2 29 Bronchopneumonia 4 
B9860 Acute MS F 2 53 Respiratory infection 6 
C0069 RRMS F 0.3 26 Bronchopneumonia 4 
B5781 SPMS F 2.7 37 Pulmonary embolism and 
inhalation pneumonia 
3 
D248 Acute MS F <2 40 Pulmonary congestion 2 
D150 PPMS F <2 23 Lung abscess, 
bronchopneumonia 
2 
D147 Acute MS F <2 33 Severe MS, pulmonary 
embolus with abscess 
3 
D192 Acute MS F 0.3 22 Hypoxic injury 5 
D134 RRMS F 4 41 Bronchopneumonia and 
pulmonary embolus 
5 
D140 Acute MS M 2 58 Sepsis 3 
D160 Acute MS M 2 51 Acute attack 1 
D200 Acute MS M <4 31 Focal haemorrhage 3 
N=12  9 F 2 yr 35 yr   
       
Prog MS Disease Gender Disease 
Duration, yr 
Age at 
Death, yr 
Cause of Death Available 
Blocks 
MS402 SPMS M 20 46 MS, bronchopneumonia 4 
MS405 SPMS M 25 62 MS, septicaemia, 
metastatic colon cancer 
4 
MS407 SPMS F 19 44 Septicaemia, pneumonia 3 
MS408 SPMS M 10 39 Pneumonia, sepsis 4 
MS422 SPMS M  58 Chest infection due to MS 4 
MS423 SPMS F 30 54 Pneumonia 4 
MS425 SPMS F 21 46 Pneumonia, MS 3 
MS438 SPMS F 18 53 MS 4 
MS461 SPMS M 21 43 Broncopneumonia 3 
MS485 PPMS F 29 57 Bronchopneumonia, MS 4 
MS491 SPMS F 26 64 Anaphylactic reaction 4 
MS492 PPMS F 31 66 Sigmoid cancer 4 
MS497 SPMS F 29 60 Aspiration pneumonia, MS 4 
MS510 SPMS F 22 38 Pneumonia, MS 4 
MS513 SPMS M 18 51 MS, respiratory failure 4 
MS517 PPMS F 25 48 Sepsis, MS 3 
MS523 SPMS F 32 63 Bronchopneumonia, MS 3 
MS527 SPMS M 25 47 Pneumonia, MS 4 
MS528 SPMS F 25 45 MS 3 
MS530 SPMS M 24 42 MS 4 
MS538 SPMS M 39 50 Pneumonia 3 
N=21 18 SPMS 12 F 25 yr 50 yr   
       
NID 
control 
Disease Gender Disease 
Duration, yr 
Age at 
Death, yr 
Cause of Death Available 
Blocks 
D095 Meningoencephalitis 
& Acute MS 
F n/d 39 Meningoencephalitis & 
ovarian tumour 
1 
91/1343 CMV M n/d 32 Bronchopneumonia 1 
C4178 CMV M n/d 59 CMV 1 
D255 CMV M n/d 32 Hypoxic injury 1 
NP13/047 ADEM M n/d 26 Pulmonary embolism 1 
RI06/166 NMO F n/d 18 Respiratory obstruction 1 
N=6  2 F  32 yr  1 
       
Control Disease Gender Disease 
Duration, yr 
Age at 
Death, yr 
Cause of Death Available 
Blocks 
NP011/13 n/a F n/a 62 Metastatic colorectal 
cancer 
2 
NP012/13 n/a F n/a 60 Metastatic breast cancer 2 
NP103/13 n/a F n/a 48 End-stage interstitial lung 
disease 
2 
NP039/13 n/a M n/a 41 Myocardial infarct 2 
NP126/13 n/a M n/a 56 Cardiac arrest 2 
NP127/13 n/a M n/a 60 Cardiac arrest 2 
NP11/093 n/a F n/a 52 Chronic Liver Disease 2 
NP1231/93 n/a M n/a 58 - 2 
NP12/088 n/a M n/a 51 Cardiac arrest 2 
NP12/052 n/a F n/a 42 Metastatic pancreatic 
carcinoma 
2 
NP12/132 n/a F n/a 67 - 2 
N=11  6 F  56 yr   
Table 1: Details of acute, progressive (Prog) multiple sclerosis, other neuroinflammatory 
disease controls (NID) and non-neurological controls (controls) used in this study. Acute MS 
defines a cohort of short disease duration and included retrospectively confirmed cases of: 
acute MS (n=8), relapsing remitting MS (n=2), secondary progressive (SP) MS (n=1) and 
primary progressive (PP) MS (n=1). Median age of death and disease duration is shown 
where applicable. ‘Available blocks’ indicates the number of unique brain tissue blocks 
analysed per case. Abbreviations; ADEM, acute disseminated encephalomyelitis; CMV, 
cytomegalovirus encephalitis; F, female; n/a, not applicable; n/d, not determined; NMO, 
neuromyelitis optica; M, male; yr, years.  
Table 2:  
Antibody 
(anti- ) 
Target Source Type/Clone Dilution 
PLP Proteolipid protein  
myelin 
Abd Serotec mAb/plpc1 1:2000 
CD68 CD68+ microglia/ macrophages Dako Cytomation mAb/KP1 1:400 
CD3 T-cells Dako Cytomation Rabbit pc 1:1200 
CD20 B-cells Dako Cytomation mAb/L26 1:125 
CD8 CD8+ T-cells Dako Cytomation C8-144B 1:100 
IBA-1 Aallograft inflammatory factor. 
Microglia/ macrophages 
FUJIFILM Wako 
Chemicals 
Rabbit pc 1:2000 
HuC/D Human HuC/D neuronal protein ThermoFisher mAb/ 16A11 1:2000 
NFil Neurofilament 200kDa Merck Millipore mAb/ RT-97 1:1000 
PCNA Proliferating cell nuclear antigen Dako Cytomation mAb/ PC10 1:1000 
Table 2: Primary antibodies used in this study. Antibody name, target cell, commercial 
source and working dilution are listed. Abbreviations; mAb, monoclonal mouse antibody; pc, 
polyclonal antibody.  
  
Table 3:  
 
Meningeal CD68+ 
(cells/ mm) 
Meningeal CD3+ 
(cells/ mm) 
Meningeal CD20+ 
(cells/ mm) 
Total Meningeal 
infiltrate  (cells/ mm) 
LLS+ parenchymal CD68 
(cells/ mm
2
) 
r=0.8810 
p= 0.0072 
r= 0.8571 
p=0.0107 
r= 0.6905 
p= 0.0694 
r= 0.8089 
p= 0.0276 
LLS- parenchymal CD68 
(cells/ mm
2
) 
r= 0.3427 
p= 0.2762 
r= 0.6434 
p=0.0278 
r= 0.4297 
p=0.2821 
r= 0.6071 
p= 0.1667 
LLS+ GML area   
(% total GM) 
r= 0.1818 
p= 0.5950 
r= 0.500 
p= 0.1217 
r= 0.6515 
p= 0.0340 
r= 0.5364 
p= 0.0939 
LLS- GML area   
(% total GM) 
r= 0.1429 
p= 0.7825 
r= 0.3214 
p= 0.4976 
r= -0.200 
p= 0.9167 
r= 0.400 
p= 0.7500 
Table 3. Relationships between meningeal inflammation (column headings) and 
parenchymal microglia/ macrophage density or grey matter lesion (GML) area in lymphoid-
like structure positive (LLS+) or negative (LLS-) cases. Significant associations are 
underlined (Spearman analysis).  
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